Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12878808 | 1.00 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL1199246 | 1.00 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL1889618 | 1.00 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL1198987 | 0.90 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL1198537 | 0.90 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL12878816 | 0.90 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL1198986 | 0.90 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL334760 | 0.88 | CXCR2 (0.78) | CXCR2 | |
| SCHEMBL10077660 | 0.88 | CXCR2 (0.78) | CXCR2 | |
| SCHEMBL1199063 | 0.86 | CXCR2 (1.00) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2009992-B1 | IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2011-03-10 | — | — | US | claimed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| EP-2009992-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007124424-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | claimed |
| EP-2009992-B1 | IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110105563-A1 | IL-8 RECEPTOR ANTAGONISTS | BUSCH-PETERSEN JAKOB | 2011-05-05 | — | — | US | disclosed |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2011-03-10 | — | — | US | disclosed |
| US-7893089-B2 | IL-8 receptor antagonists | GlaxoSmithKline, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| EP-2009992-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007124424-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249672-A1 | IL-8 Receptor Antagonists | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105563-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 12/4885 |
| US-20070249672-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885 |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 12/4885 |
| US-20090093451-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.